Bo Wang Pharmaceuticals: The innovative drug BW-20507 for the treatment of chronic hepatitis B has completed Phase II clinical trials with the first patient receiving the medication.

On September 8th, Beiwang Pharmaceutical Co., Ltd. announced that the Phase II clinical trial of a new drug, BW-20507, developed independently by the company, has completed the first patient dosing for the treatment of chronic hepatitis B. Prior to this, in June 2025, this therapy obtained the approval for Phase II clinical trials from the China National Medical Products Administration. This Phase II clinical trial will evaluate BW-20507 monotherapy and the use of BW-20507 in combination with long-acting interferon for treatment.